-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, F-star Therapeutics, a bispecific immunotherapy research and development company, announced that it has signed a license and cooperation agreement for bispecific antibody therapy with Janssen Biotech, one of Johnson & Johnson's Janssen pharmaceutical companies
.
According to the terms of the agreement, F-star will grant Janssen a global exclusive license to use its proprietary Fcab and mAb2 technologies for the research, development and commercialization of up to 5 new bispecific antibody platforms against Janssen's therapeutic targets
.
In terms of finances, F-star has the right to charge up to US$17.
F-star's proprietary bispecific antibody technology platform can be replaced in the Fc region or tail of natural antibodies
.
This technology can create two different antigen binding sites, forming the so-called "Fcab building block" in the field of biotechnology
Currently, Fcab and mAb2 technologies have 230 patents, and another 150 are pending for approval
.
Janssen will be responsible for all research, development and commercialization activities under the agreement
The latest large-value transactions have further enriched the company's cooperation lineup
.
In July of this year, F-star announced that it has signed an exclusive license agreement with AstraZeneca, and AstraZeneca has obtained the global right to research, develop and commercialize next-generation interferon gene stimulating protein (STING) inhibitor compounds, and Responsible for all research, development and commercialization of STING inhibitor compounds, and F-star will retain the rights to all STING inhibitor compounds
Through cooperation with AstraZeneca, F-star will also be eligible for up to 12 million U.
S.
dollars in advance and recent payments, and will also be eligible for more than 300 million U.
S.
dollars in development and sales milestone payments, as well as single-digit percentage concessions.
Royalties
.
The company's other partners include Merck KGaA, Denali Therapeutics, Bristol-Myers Squibb (BMS) and AbbVie
Affected by this good news, F-star's share price rose about 13% to 7.
Reference source:
Reference source:1.
1.
2.
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
